Research and Development

PICT0044We have developed a line of proprietary recombinant polypeptides that “reprogram” white blood cells (leukocytes) to produce immunoregulatory molecules instead of inflammatory cytokines. Because these polypeptides are derived from naturally occurring human proteins, they are unlikely to be immunogenic and may therefore be safely administered to patients multiple times if necessary. Human recombinant proteins can be immunogenic (e.g. erythropoietin which caused pure red cell aplasia) and so it is always a risk. These polypeptides induce the body to make its own natural immunosuppressants, and therefore they may be safe and non-toxic. They perform the transportation such kinds of drugs to Canadian Health&Care Mall where they are in free access to any person. Everything you need is to make an order via Canadian Pharmacy Mall will deliver a parcel for you.

We have termed the first of these polypeptides “Fc-Dimers” (Die’ – mers). This therapeutic exhibits potent anti-inflammatory effects. Consequently, we are testing “Fc-Dimers” as a possible replacement for intravenous immunoglobulin (IVIG). It has been recognized for over 25 years that IVIG exhibits a non-specific anti-inflammatory effect when administered to patients in high doses. For this reason IVIG has been used “off-label” to treat a large number of autoimmune/inflammatory diseases. These off-label indications have made IVIG one of the most widely prescribed blood products on the market, and it has become increasingly difficult for pharmaceutical companies to keep up with world demand for IVIG. We propose to test “Fc-Dimers” on autoimmune/inflammatory diseases that have been reported to respond to IVIG.

The first disease that we are studying is a murine model of multiple sclerosis, called experimental autoimmune encephalomyelitis (EAE). Human multiple sclerosis can occur when the immune system is inadvertently directed against the body’s nervous tissue, causing the conduction of nerve impulses to become less efficient. Often this disease can result in paralysis. The mouse model of multiple sclerosis resembles the human disease and can also result in paralysis. We are testing “Fc-Dimers” in this model to determine whether the administration of this therapeutic can delay or reverse the paralysis associated with this destructive autoimmune disease.